Molecular profile of IMFT for the identification of potential druggable targets and biomarkers predicting crizotinib response.
收藏NIAID Data Ecosystem2026-03-14 收录
下载链接：
https://www.omicsdi.org/dataset/ega/EGAS00001005419
下载链接
链接失效反馈官方服务：
资源简介：
The clinical phase II trial EORTC 90101 “CREATE†showed high anti-tumor activity of crizotinib, an ALK/ROS1 inhibitor, in IMFT patients. However, results suggested that other molecular targets in addition to ALK/ROS1 might also contribute to the sensitivity of this kinase inhibitor. We therefore characterized molecular profile of IMFT to identify alterations which could play a role in the response to crizotinib.EGA study EGAS00001005419
创建时间：
2023-02-02
